Biotech | October 01, 2021
Jubilant concludes pre-IND meeting of JB1-802 with U.S. FDA
The company plans to submit the IND application by the end of 2021
The company plans to submit the IND application by the end of 2021
The acquisition complements and strengthens Merck’s cardiovascular pipeline
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
These pouches, manufactured at UFlex India plant, will be exported to American markets and will be majorly used for packing edible products
The aspirant can enrol in MBA (Healthcare and Hospital Management) at Ganpat University, -Centre for Management Studies and Research, which will be facilitated by Ganpat University and Shalby Centre for Healthcare Management and Research
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
It is a recombinant nanoparticle protein-based vaccine
Subscribe To Our Newsletter & Stay Updated
